The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasiawho failed to obtain sufficient efficacy by previous alpha-1-blockades. . A comparison of Naftopidil or Silodosin.

The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasiawho failed to obtain sufficient efficacy by previous alpha-1-blockades. . A comparison of Naftopidil or Silodosin. - The effects of selective alpha-1- adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia. A comparison of Naftopidil or Silodosin.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003609

Enrollment

100

Registered

2010-05-16

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

We assess the clinical efficacy and safety of the loading dosage escalation to naftopidil 75mg in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Men with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain sufficient efficacy by naftopidil 50mg and with International Prostate Symptom Score(IPSS) of>=9,a quality-of-life (QOL)score of >=2,a prostate volume of>=20ml are eligible for enrolment.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
IPSS score QOL score Blood pressure	—

Secondary

Measure	Time frame
Uroflowmetry	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026